US 11,884,943 B2
Engineered Pyrococcus enzymes and uses thereof
Souad Naji, La Jolla, CA (US); Eli N. Glezer, La Jolla, CA (US); Youngjin Cho, La Jolla, CA (US); Zachary Terranova, La Jolla, CA (US); and Abrehet Abdu, La Jolla, CA (US)
Assigned to Singular Genomics Systems, Inc., La Jolla, CA (US)
Filed by Singular Genomics Systems, Inc., La Jolla, CA (US)
Filed on Oct. 5, 2021, as Appl. No. 17/494,668.
Application 17/494,668 is a continuation of application No. PCT/US2021/019466, filed on Feb. 24, 2021.
Application PCT/US2021/019466 is a continuation of application No. 16/803,763, filed on Feb. 27, 2020, granted, now 11,034,942, issued on Jun. 15, 2021.
Prior Publication US 2022/0119780 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01); C12N 15/63 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6874 (2018.01)
CPC C12N 9/1252 (2013.01) [C12N 15/63 (2013.01); C12Q 1/6874 (2013.01); C12Y 207/07007 (2013.01)] 19 Claims
 
1. A polymerase comprising an amino acid sequence that is at least 80% identical to a continuous 500 amino acid sequence within SEQ ID NO: 1; comprising the following amino acids:
an alanine at amino acid position 409 or an amino acid position functionally equivalent to amino acid position 409;
a glycine at amino acid position 410 or an amino acid position functionally equivalent to amino acid position 410;
a proline at amino acid position 411 or an amino acid position functionally equivalent to amino acid position 411; and
a glutamine, arginine, or alanine at amino acid position 93 or an amino acid position functionally equivalent to amino acid position 93.